Zydus Life gets FDA nod for children’s lung treatment drug bosentan
Zydus Life gets FDA nod for children’s lung treatment drug bosentan is drawing significant interest across the industry.
Zydus Lifesciences Ltd received US FDA approval for bosentan tablets for oral suspension, 32 mg, for pulmonary arterial hypertension (PAH) treatment. Shares of Zydus Lifesciences Ltd ended marginally higher on Wednesday, February 18, by 0.65% at ?912.50 on the NSE.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Lil Poppa girlfriend and relationships: All about Toie Roberts, baby momma of rapper signed to Yo Gotti's CMG
- Rishab Agarwal’s Petition Challenging WeWork India IPO Disclosures Withdrawn Unconditionally
- Zelenskiy Prioritizes Security Amidst Ongoing Russian Attacks
- Gautami Kapoor Takes a Break from Social Media Amid Toxic Comments
Source: Original →